AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,184,804 | -7.6% | 43,195 | -14.7% | 0.00% | 0.0% |
| Q2 2023 | $2,363,402 | +120.0% | 50,619 | +80.3% | 0.00% | +100.0% |
| Q1 2023 | $1,074,379 | -26.4% | 28,081 | +5.4% | 0.00% | -50.0% |
| Q4 2022 | $1,459,817 | +231.0% | 26,639 | +105.3% | 0.00% | – |
| Q3 2022 | $441,000 | +261.5% | 12,976 | +1.2% | 0.00% | – |
| Q2 2022 | $122,000 | -23.3% | 12,827 | +14.8% | 0.00% | – |
| Q1 2022 | $159,000 | -30.6% | 11,178 | +3.1% | 0.00% | – |
| Q4 2021 | $229,000 | -66.4% | 10,838 | -64.5% | 0.00% | – |
| Q3 2021 | $682,000 | +166.4% | 30,572 | +195.8% | 0.00% | – |
| Q2 2021 | $256,000 | -21.5% | 10,337 | -7.8% | 0.00% | – |
| Q1 2021 | $326,000 | -55.6% | 11,215 | -60.7% | 0.00% | – |
| Q4 2020 | $735,000 | +141.8% | 28,503 | +188.5% | 0.00% | – |
| Q3 2020 | $304,000 | – | 9,879 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |